Scholar Rock Holding buy Barclays PLC
Start price
24.09.25
/
50%
€28.80
Target price
24.09.26
€37.29
Performance (%)
9.72%
Price
08:49
€31.60
Summary
This prediction is currently active. With a performance of 9.72%, the BUY prediction by Barclays_PLC for Scholar Rock Holding is trending in the right direction. This prediction currently runs until 24.09.26. The prediction end date can be changed by Barclays_PLC at any time. Barclays_PLC has 50% into this predictionScholar Rock is a clinical-stage biopharmaceutical company that engages in the discovery and development of innovative medicines to treat serious diseases in patients that currently have limited or no treatment options. Their pipeline consists of a number of product candidates that target growth factor signaling pathways within the human body. These products hold potential for the treatment of multiple diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock, which trades under the symbol SRRK, is listed on the NASDAQ stock exchange.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Scholar Rock Holding | -6.627% |
| iShares Core DAX® | 2.709% |
| iShares Nasdaq 100 | 0.867% |
| iShares Nikkei 225® | 3.135% |
| iShares S&P 500 | 0.886% |
Comments by Barclays_PLC for this prediction
In the thread Scholar Rock Holding diskutieren
Scholar Rock (NASDAQ:SRRK) had its price target lowered by analysts at Barclays PLC from $45.00 to $44.00. They now have an "overweight" rating on the stock.
Ratings data for SRRK provided by MarketBeat
Stopped prediction by Barclays_PLC for Scholar Rock Holding
Scholar Rock Holding
Start price
Target price
Perf. (%)
€28.60
17.09.25
17.09.25
€37.96
17.09.26
17.09.26
10.49%
08:49
08:49
